2.5605  -0.35 (-12.01%)		12-15 15:59
Open: 2.97 High: 3.09 Volume: 122,054		Pre. Close: 2.91 Low: 2.48 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	4.49	1-year :	5.48
Resists	First :	3.85	Second :	4.69
Pivot price	3.62
Supports	First :	2.48	Second :	2.06
MAs	MA(5) :	3.52	MA(20) :	3.54
	MA(100) :	14.88	MA(250) :	0
MACD	MACD :	-1.2	Signal :	-1.6
%K %D	K(14,3) :	6.6	D(3) :	32.8
RSI	RSI(14): 26.8
52-week	High :	33.7	Low :	2.48

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NCEL ] has closed below the lower bollinger band by 6.3%. Bollinger Bands are 73.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.09 - 3.12	3.12 - 3.13
Low:	2.43 - 2.46	2.46 - 2.48
Close:	2.53 - 2.56	2.56 - 2.59

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

Tue, 04 Nov 2025
NewcelX CEO Issues Letter to Shareholders - Nasdaq

Mon, 03 Nov 2025
NLS Pharmaceutics and Kadimastem merge to form NewcelX - Switzerland Global Enterprise

Thu, 30 Oct 2025
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger - PR Newswire

Wed, 29 Oct 2025
NLS Pharmaceutics (NASDAQ: NLSP) to list NewCelX; Kadimastem delisting Oct. 31 - Stock Titan

Wed, 29 Oct 2025
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem - PR Newswire

Tue, 28 Oct 2025
NLS Pharmaceutics and Kadimastem Finalize Merger Conditions - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	5 (M)
Shares Float	2 (M)
Held by Insiders	71.3 (%)
Held by Institutions	4.5 (%)
Shares Short	13 (K)
Shares Short P.Month	159 (K)

EPS	-6.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-11.28
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-155.2 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	37 (M)

PE Ratio	-0.41
PEG Ratio	0
Price to Book value	-0.23
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.